扶正消瘤颗粒联合卡瑞利珠单抗与阿帕替尼治疗晚期原发性肝癌临床观察  

Observation on Fuzhengxiaoliu glonules combincd carrelizumab and apatinib mesylate in the treatment of advanced primary liver cancer under the intervention of traditional Chinese medicine

作　　者：杨荷 陈晓琦 王新亭 张传雷 袁长威 杨芳明 陈欣菊 赵文霞[2] YANG He;CHEN Xiao-qi;WANG Xin-ting;CHEN Xin-ju(The First Clinical Medical College of Henan University of Chinese Medicine,Zhengzhou Henan,450046,China;不详)

机构地区：[1]河南中医药大学第一临床医学院,河南郑州450046 [2]河南中医药大学第一附属医院

出　　处：《中西医结合肝病杂志》2021年第8期679-682,共4页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：国家科技重大专项-艾滋病和病毒性肝炎等重大传染病防治(No.2018ZX10303502)。

摘　　要：目的:观察在扶正消瘤颗粒干预下,卡瑞利珠单抗联合甲磺酸阿帕替尼治疗晚期原发性肝癌患者的临床疗效及不良反应。方法:回顾性分析2017年12月1日至2020年12月1日接受扶正消瘤颗粒联合卡瑞利珠单抗、阿帕替尼治疗的44例晚期原发性肝癌患者,记录患者一般情况、实验室及影像学资料、不良反应,并随访其预后及死亡情况。结果:至随访截止时间,44例患者均接受了至少2次卡瑞利珠单抗治疗,其中7例(15.91%)部分缓解(PR),23例(52.27%)疾病稳定(SD),14例(31.82%)疾病进展(PD)。客观缓解率(ORR)为15.91%,疾病控制率(DCR)为68.18%。截止随访时间,17例患者存活,27例患者死亡,3个月生存率为90.91%,6个月生存率为65.91%,总生存率为38.64%,Kaplan-Meier法预估中位无进展生存期(PFS)为5个月,中位生存期(OS)为11个月。主要不良反应为乏力,食欲下降,皮疹,甲状腺功能异常,肝功能受损,大多为轻度不良反应,3级及以上不良反应发生率为11.36%。结论:扶正消瘤颗粒可提高卡瑞利珠单抗联合阿帕替尼治疗晚期肝癌的临床疗效,减轻不良反应,延长晚期肝癌患者生存时间。Objective:To observe the clinical efficacy and adverse reactions of carrelizumab combined with apatinib mesylate in the treatment of advanced primary liver cancer under the intervention of traditional Chinese medicine.Methods:A retrospective analysis of 44 patients with advanced primary liver cancer treated with FuzhengXiaoliu Granules combined with carrelizumab and apatinib from December 1,2017 to December 1,2020,the records were average conditions,laboratory and imaging data,adverse reactions,and follow-up prognosis and death.Results:As of the follow-up cut-off time,all 44 patients had received at least 2 treatments with PD-1 monoclonal antibody,including 7 cases of PR(15.91%,7/44),23 cases of SD(52.27%,23/44),14 Example of PD(31.82%,14/44).ORR was 15.91%,and DCR was 68.18%.By the time of follow-up,17 patients were alive and 27 patients died.The 3-month survival rate was 90.91%(40/44),and the 6-month survival rate was 65.91%(29/44),and the overall survival rate was 38.64%.Kaplan-Meier According to the method,the median progression free survival(PFS)was 5 months,and the median survival(OS)was 11 months.The main adverse reactions were fatigue,decreasedappetite,skin rash,abnormal thyroid function,and liver function damage.Most of them were mild adverse reactions.The incidence of grade 3 and above adverse reactions was 11.36%.Conclusion:FuzhengXiaoliu Granules can increase the efficacy of carrelizumab combined with apatinib in the treatment of advanced liver cancer,reduce adverse reactions,and prolong the survival time of patients with advanced liver cancer.

关 键 词：扶正消瘤颗粒 卡瑞利珠单抗 甲磺酸阿帕替尼 晚期原发性肝癌 

分 类 号：R259[医药卫生—中西医结合]